Skip to main content
. 2022 Nov 10;14(22):5537. doi: 10.3390/cancers14225537

Table 1.

Baseline sociodemographic and clinical characteristics of the individuals with hematological disease who were recruited for this study.

Patients (n = 18) Healthy Controls (n = 15)
Age, median (IQR) 61 (53.2–72.8) 77 (72.0–79.0)
Sex: Female, n (%) 12 (66.66) 12 (80%)
Diagnosis
  • -

    NHL, n (%)

  • -

    AIHA, n (%)

  • -

    IT/SLE, n (%)

 16 (88.89)
1 (5.56)
1 (5.56)		 -
-
-
Number of doses of rituximab, n (%)
  • -

    4 doses

  • -

    6 doses

  • -

    >8 doses

 4 (22.22)
9 (50)
5 (27.78)		 -
-
-
Concomitant chemotherapy within 18 months prior to booster, n (%)
  • -

    None

  • -

    Prednisone

  • -

    CHOP

  • -

    Bendamustine

  • -

    Loncastuximab

  • -

    Radiotherapy

  • -

    Methotrexate

 4 (22.22)
2 (11.11)
10 (55.56)
2 (11.11)
1 (5.56)
2 (11.11)
1 (5.56)		 -
-
-
-
-
-
-
Months from last treatment with rituximab to second vaccine dose, median (IQR) 9.6 (6–15) -
Months from last treatment with rituximab to third vaccine dose, median (IQR) 13.8 (9.4–19) -
Days from second dose to first sample, median (IQR) 124.5 (122.75–126) 189.3 (184–189)
Days from booster dose to second sample, median (IQR) 28 (28–33.5) 29 (29.0–42.5)

AIHA, autoimmune hemolytic anemia; CHOP, cyclophosphamide, doxorrubicine, vincristine, prednisone; IQR, interquartile range; IT, immune thrombocytopenia; NHL, non-Hodgkin’s lymphoma; SLE, systemic lupus erythematosus.